

Celgene - ABRAXANE + Pipeline Drugs = Long Term Growth!

https://marketpublishers.com/r/CB131E11A2FEN.html

Date: November 2012 Pages: 7 Price: US\$ 140.00 (Single User License) ID: CB131E11A2FEN

Abstracts

Despite setback to Revlimid's label expansion in 1st line RRMM and as maintenance therapy in EU, Celgene (CELG) 3Q12 earnings highlighted growth of Revlimid globally on both a YoY and sequential basis. We do not see risk to Revlimid's growth for at least the next 4 years and expect double digit sales CAGR, healthy cash flow and approval of new products (Pomalidomide, Apremilast, label expansion of ABRAXANE). Should ongoing PhIII studies of Revlimid - MM-015 (NDDMM & maintenance), IFM 2009-05 (Post-ASCT maintenance), MM-020 FIRST (NDMM) and CALGB 100104 (Post-ASCT maintenance) demonstrate significant OS and no further increase in malignances, EU approval may also come by 2014. Positive data from ABRAXANE trials in melanoma and pancreatic cancer.....please read our report released on 11th Nov. 2012, titled, 'ABRAXANE + Pipeline Drugs = Long Term Growth!'



I would like to order

Product name: Celgene - ABRAXANE + Pipeline Drugs = Long Term Growth! Product link: <u>https://marketpublishers.com/r/CB131E11A2FEN.html</u>

> Price: US\$ 140.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/CB131E11A2FEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970